Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which are RAAS blockers, demonstrated benefits in preventing CKD progression and are, therefore, considered as first-line antihypertensive drugs in patients with diabetes mellitus, hypertension, eGFR 60 mL/min/1.73 m2, and urine albumin-to-creatinine ratio (UACR) 300 mg/g Cr. The gene discussed is ACE; the disease is hypertensive disorder.